| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Reproductive Endocrine Unit (Y.S., A.L.S.) and Endocrine Unit (H.T.K.), Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114
Address all correspondence and requests for reprints to: Henry T. Keutmann, Endocrine Unit, Wellman 501, Massachusetts General Hospital, Boston, Massachusetts 02114. E-mail: Keutmann{at}helix.mgh.harvard.edu.
Local regulation of pituitary FSH secretion and many other cellular processes by follistatin (FS) can be ascribed to its potent ability to bind and bioneutralize activin, in conjunction with binding to cell surface heparan-sulfate proteoglycans through a basic heparin-binding sequence (HBS; residues 75–86) in the first of the three FS domains. The FS homolog, FSTL3, also binds activin, but lacks any HBS and cannot associate with cell surfaces. We have used mutational analyses to define the determinants for heparin binding and activin interaction in FS and to determine the effects of conferring heparin binding to FSTL3. Mutants expressed from 283F cells were tested for cell surface and heparin affinity binding, for competititive activin binding and for bioactivity by suppression of pituitary cell FSH secretion. Replacement of the HBS or the full-length FS-domain 1 abolished cell surface binding but enhanced activin binding 4- to 8-fold. Surface binding was partially reduced after mutation of either lysine pair 75/76 or 81/82 and eliminated after mutation of both pairs. The 75/76 mutation reduced activin binding and, therefore, pituitary cell bioactivity by 5-fold. However, insertion of the HBS into FSTL3 did not restore heparin binding or pituitary-cell bioactivity. These results show that 1) the residues within the HBS are necessary but not sufficient for heparin binding, and 2) the HBS also harbors determinants for activin binding. Introduction of the full domain from FS conferred heparin binding to FSTL3, but activin binding was abolished. This implies an evolutionary safeguard against surface binding by FSTL3, supporting other evidence for physiological differences between FS and FSTL3.
This article has been cited by other articles:
 |
|
 |
|
  Y. Xia and A. L Schneyer The biology of activin: recent advances in structure, regulation and function J. Endocrinol., July 1, 2009; 202(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. F. Lerch, S. Shimasaki, T. K. Woodruff, and T. S. Jardetzky Structural and Biophysical Coupling of Heparin and Activin Binding to Follistatin Isoform Functions J. Biol. Chem., May 25, 2007; 282(21): 15930 - 15939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sidis, A. Mukherjee, H. Keutmann, A. Delbaere, M. Sadatsuki, and A. Schneyer Biological Activity of Follistatin Isoforms and Follistatin-Like-3 Is Dependent on Differential Cell Surface Binding and Specificity for Activin, Myostatin, and Bone Morphogenetic Proteins Endocrinology, July 1, 2006; 147(7): 3586 - 3597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-G. Chen, Q. Wang, S.-L. Lin, C. D. Chang, J. Chung, and S.-Y. Ying Activin Signaling and Its Role in Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis. Experimental Biology and Medicine, May 1, 2006; 231(5): 534 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Utriainen, J. Liu, T. Kuulasmaa, and R. Voutilainen Inhibition of DNA methylation increases follistatin expression and secretion in the human adrenocortical cell line NCI-H295R J. Endocrinol., February 1, 2006; 188(2): 305 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Kumar Too Many Follistatins: Racing Inside and Getting Out of the Cell Endocrinology, December 1, 2005; 146(12): 5048 - 5051. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
